Kymera Therapeutics, Inc. (KYMR)
131.73
+3.61
(+2.82%)
USD |
NASDAQ |
Nov 06, 16:00
131.70
-0.03
(-0.02%)
After-Hours: 20:00
Kymera Therapeutics Enterprise Value : 10.35B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 10.35B |
| November 05, 2026 | 10.04B |
| November 04, 2026 | 10.73B |
| November 03, 2026 | 9.949B |
| November 02, 2026 | 9.985B |
| October 30, 2026 | 9.910B |
| October 29, 2026 | 9.566B |
| October 28, 2026 | 9.559B |
| October 27, 2026 | 9.137B |
| October 26, 2026 | 8.904B |
| October 23, 2026 | 8.556B |
| October 22, 2026 | 8.564B |
| October 21, 2026 | 8.716B |
| October 20, 2026 | 8.786B |
| October 19, 2026 | 8.327B |
| October 16, 2026 | 8.046B |
| October 15, 2026 | 8.332B |
| October 14, 2026 | 8.221B |
| October 13, 2026 | 8.208B |
| October 12, 2026 | 8.669B |
| October 09, 2026 | 8.696B |
| October 08, 2026 | 8.431B |
| October 07, 2026 | 8.350B |
| October 06, 2026 | 8.148B |
| October 05, 2026 | 8.478B |
| Date | Value |
|---|---|
| October 02, 2026 | 8.268B |
| October 01, 2026 | 8.501B |
| September 30, 2026 | 8.644B |
| September 29, 2026 | 8.537B |
| September 28, 2026 | 8.660B |
| September 25, 2026 | 8.656B |
| September 24, 2026 | 8.975B |
| September 23, 2026 | 8.947B |
| September 22, 2026 | 9.493B |
| September 21, 2026 | 9.129B |
| September 18, 2026 | 9.136B |
| September 17, 2026 | 9.196B |
| September 16, 2026 | 9.018B |
| September 15, 2026 | 8.755B |
| September 14, 2026 | 8.878B |
| September 11, 2026 | 8.905B |
| September 10, 2026 | 9.074B |
| September 09, 2026 | 8.944B |
| September 08, 2026 | 9.030B |
| September 04, 2026 | 9.106B |
| September 03, 2026 | 9.097B |
| September 02, 2026 | 9.209B |
| September 01, 2026 | 9.244B |
| August 31, 2026 | 9.224B |
| August 28, 2026 | 9.169B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.348B |
| Twist Bioscience Corp. | 7.497B |
| Beam Therapeutics, Inc. | 1.932B |
| C4 Therapeutics, Inc. | 256.91M |
| Arrowhead Pharmaceuticals, Inc. | 7.983B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -132.00M |
| Total Expenses (Quarterly) | 132.00M |
| EPS Diluted (Quarterly) | -1.319 |
| Earnings Yield | -2.75% |
| Normalized Earnings Yield | -2.748 |